CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

ID Week 2022

Infectious Diseases Week 2022

October 19 - 23, 2022 
Hybrid

  • Cabotegravir

    Poteat T, et al.

    Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Oral Presentation.

    View Poster

    Poteat T, et al.

    PrEP Interest and Preferences Among US Black and Hispanic Men – A National Survey. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Sanchez T, et al.

    Relative Patient Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Pre-exposure Prophylaxis Among US Men Who Have Sex With Men, 2021-2022. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Hot Zone Poster.

    View Poster

    DeWit S, et al.

    CARISEL: A Hybrid III Implementation Effectiveness Study of Implementation of Cabotegravir Plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Oral Presentation.

    View Poster

    Hsu R, et al.

    US Healthcare Provider Perspectives on the Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world Study (BEYOND). Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Patel P, et al.

    Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Oral Presentation.

    View Poster

  • Dolutegravir

    Benson P, et al.

    Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment With Baseline Viral Loads ≥100,000 Copies/mL in the US. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    de Wet JJ, et al.

    A Real-world Observational Study on HIV-Infected Patients Who Switched From Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Kuretski JP, et al.

    Real World Treatment Experience of Treatment-Naïve People With HIV Who Initiated Treatment With Single Tablet Dolutegravir/Lamivudine in a Test and Treat Setting in the US. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Prakash M, et al.

    Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results From the TANGO and SALSA Studies. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Slim J, et al.

    Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in People With HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Yan L, et al.

    Effectiveness and Durability of Dolutegravir (DTG) Based Regimens in Older People Living With HIV (PLWH) From the Veterans Aging Cohort Study (VACS). Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

  • Disease State

    Brogan AP, et al.

    An Increase in Single-Tablet Regimen (STR) Utilization for People Living With HIV (PLWH) Enrolled in Medicaid Had Minimal Impact on Pharmacy Costs. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Brogan AP, et al.

    Single-Tablet Regimens (STR) Offer Better Persistence and Adherence, With Lower Costs by Adherence Status, Than Multiple-Tablet Regimens (MTR) for People Living With HIV (PLWH) Enrolled in Medicaid. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

    Dominguez M, et al.

    Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV. Presented at IDWeek 2022, October 19-23, 2022, Washington, D.C. and virtually. Poster.

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

My MSL

Enter zip code to find your MSL contact.